![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » GILEAD, MERCK TO SUPPLY ATRIPLA IN KENYA
GILEAD, MERCK TO SUPPLY ATRIPLA IN KENYA
Gilead Sciences and Merck have signed an agreement to distribute the new single-dose, once-a-day HIV drug Atripla in Kenya, reports The Nation, based in Nairobi, Kenya. The FDA approved the drug in July, and Bristol-Myers Squibb and Gilead market it in the U.S.
The FDA also approved an alternate version of Atripla (efavirenz/emtricitabine/tenovir disoproxil fumarate) for developing countries in form of a white-colored tablet to distinguish it from the salmon-colored version sold in the United States, according to The Nation.
Gilead and Merck planned to pursue registration of the product with individual country health authorities, according to a joint statement released in Nairobi and obtained by The Nation. According to the agreement, Gilead will manufacture Atripla with efavirenz supplied by Merck, which will also handle distribution.
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
21Oct